Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon
P
P
AB Astra Hässle, Mölndal, Sweden.
Bayati
A
A
Lee
H
H
Andersson
K
K
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D001562:Benzimidazoles / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000201:enzymology*; D017506:H(+)-K(+)-Exchanging ATPase / Q000737:chemistry; D006801:Humans; D007700:Kinetics; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D013329:Structure-Activity Relationship; D013454:Sulfoxides / Q000737:chemistry / Q000494:pharmacology; D014634:Valinomycin / Q000494:pharmacology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D014634:Valinomycin; D064750:Rabeprazole; D000077402:Pantoprazole; D017506:H(+)-K(+)-Exchanging ATPase; D009853:Omeprazole